{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:28:42Z","timestamp":1792794522865,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"grant-in-aid for scientific research from the Japan Society of the Promotion of Science","award":["JP20K08817"],"award-info":[{"award-number":["JP20K08817"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the antibody response to 13-valent pneumococcal conjugate vaccine (PCV13) in patients with rheumatoid arthritis receiving Janus kinase inhibitors (JAKIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifty-three patients receiving methotrexate (MTX; n\u2009=\u200910), JAKI (n\u2009=\u200920), or MTX\u2009+\u2009JAKI (n\u2009=\u200923) were vaccinated with PCV13. Serum concentrations of immunoglobulin G (IgG) antibodies to 13 pneumococcal serotype capsular polysaccharides were quantified before and 4\u20136\u2009weeks after vaccination. Positive antibody response was defined as a 2-fold or more increase in IgG concentrations from prevaccination levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After vaccination, IgG concentrations significantly increased in all treatment groups (P &amp;lt;0.001), but fold increases (postvaccination to prevaccination ratios) were different among treatment groups (9.30 for MTX, 6.36 for JAKI, and 3.46 for combination therapy). Positive antibody response rates were comparable between the MTX group (90%) and the JAKI group (95%) but lower in the MTX\u2009+\u2009JAKI group (52.2%). In a multivariable logistic regression analysis, the combination therapy was the only factor associated with a reduced antibody response to PCV13. No severe adverse events were observed in any treatment group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although JAKIs do not impair PCV13 immunogenicity in rheumatoid arthritis patients, the combination of MTX with JAKI can reduce the antibody response in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roac029","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T09:20:09Z","timestamp":1648545609000},"page":"312-317","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Janus kinase inhibitors on antibody response to 13-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-4252","authenticated-orcid":false,"given":"Shunsuke","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, National Hospital Organization Kumamoto Saishun Medical Center , Kohshi, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[{"name":"Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital , Sasebo, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhiko","family":"Ishiwada","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medical Mycology Research Center, Chiba University , Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,26]]},"reference":[{"key":"2023030304341437000_","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001041","article-title":"Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD","volume":"5","author":"Furer","year":"2019","journal-title":"RMD Open"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.vaccine.2015.01.065","article-title":"Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort","volume":"33","author":"Hmamouchi","year":"2015","journal-title":"Vaccine"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153848","article-title":"Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: a retrospective cohort study using data from the Clinical Practice Research Datalink","volume":"11","author":"Costello","year":"2016","journal-title":"PLoS One"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/03009742.2016.1242774","article-title":"Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA)","volume":"46","author":"Nguyen","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells","volume":"205","author":"Clutterbuck","year":"2012","journal-title":"J Infect Dis"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40266-013-0060-5","article-title":"Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice","volume":"30","author":"Vila-Corcoles","year":"2013","journal-title":"Drugs Aging"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist","volume":"43","author":"Friedman","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J Rheumatol"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3949\/ccjm.87a.20056","article-title":"The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults","volume":"87","author":"Day","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1883-1","article-title":"Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy","volume":"21","author":"Winthrop","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023030304341437000_","article-title":"Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients","volume":"17","author":"Migita","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.30580","article-title":"Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors","volume":"63","author":"Kapetanovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202658","article-title":"Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy","volume":"72","author":"Mori","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/14397595.2013.843743","article-title":"Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab","volume":"24","author":"Tsuru","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)","volume":"74","author":"Bingham","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s10067-011-1856-5","article-title":"Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs","volume":"30","author":"Kapetanovic","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0019-6","article-title":"Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjogren\u2019s syndrome without disease modifying treatment","volume":"2","author":"Nived","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/M20-0046","article-title":"Advisory Committee on Immunization P. Recommended adult immunization schedule, United States, 2020","volume":"172","author":"Freedman","year":"2020","journal-title":"Ann Intern Med"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3899\/jrheum.161407","article-title":"Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: results of a randomized controlled trial","volume":"44","author":"Nguyen","year":"2017","journal-title":"J Rheumatol"},{"key":"2023030304341437000_","article-title":"Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients","volume":"22","author":"Nived","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023030304341437000_","first-page":"898","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","article-title":"Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14740338.2022.2006180","article-title":"Search of official nationwide database in Japan for adverse events associated with disease-modifying antirheumatic drug therapies: focus on therapies in combination with methotrexate","volume":"21","author":"Inokuma","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"2023030304341437000_","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0663-9","article-title":"Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases\u2014a longitudinal study","volume":"17","author":"Fischer","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2023030304341437000_","article-title":"Impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases","volume":"9","author":"Richi","year":"2021","journal-title":"Vaccines (Basel)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac029\/43385874\/roac029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/312\/49400536\/roac029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/312\/49400536\/roac029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T06:02:13Z","timestamp":1700373733000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/2\/312\/6554505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,26]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,26]]},"published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac029","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,3,26]]}}}